trending Market Intelligence /marketintelligence/en/news-insights/trending/vFlg8ZSbA2SUR7BqTB7F4A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Anika Therapeutics enters agreements to acquire Parcus Medical, Arthrosurface

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Anika Therapeutics enters agreements to acquire Parcus Medical, Arthrosurface

Anika Therapeutics Inc. entered into agreements to acquire sports medicine company Parcus Medical LLC and orthopedic medical device company Arthrosurface Inc.

Bedford, Mass.-based Anika will make an up-front cash payment of about $35 million to Parcus, with an additional $60 million upon reaching certain commercial milestones for the acquisition.

Under the agreement signed with Arthrosurface, Anika will pay an up-front cash payment of about $60 million, with an additional $40 million upon reaching certain regulatory and commercial milestones.

Anika provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions. The company said the acquisitions will help broaden its product portfolio into joint preservation and restoration, add high-growth and diversified revenue streams, expand its research and development expertise and make its commercial capabilities stronger.

As part of the deals, the executive teams of Parcus and Arthrosurface led by President Mark Brunsvold and President and CEO Steven Ek, respectively, will join Anika continuing to lead the companies' business.

"Parcus Medical provides direct access to the high-growth ambulatory surgery center market, which will enable Anika to source new revenue streams, and Arthrosurface has an innovative product pipeline and an established direct hybrid sales model, which will accelerate our product platform strategy," Anika's president and CEO Joseph Darling said in a Jan. 6 news release.

Anika expects the acquisitions, which are subject to approvals by the unitholders and shareholders of Parcus and Arthrosurface, respectively, to be completed in the first quarter of the year.

Parcus Medical is expected to generate about $12 million to $13 million of revenue for the full year of 2019, an increase of about 15% compared to the prior year.

SVB Leerink LLC served as the exclusive financial adviser to Anika while Sullivan & Cromwell LLP served as Anika's legal counsel for the transactions.